Kos Submits Supplemental New Drug Application To FDA For New Niaspan(R) CF Range of Products (Business Wire via Yahoo! Finance)
CRANBURY, N.J.----July 12, 2006--Kos Pharmaceuticals, Inc. : Includes new optimized 1000mg Niaspan CF formulation that has demonstrated an improved overall flushing profile vs. currently commercialized Niaspan, with a 42 percent reduction in severity, and a 43 percent reduction in duration of flushing Niaspan CF launch planned for first quarter 2007 Plans in place to incorporate optimized

Cyberonics Receives FDA Approval for Harmonized/Modularized VNS Therapy System Labeling Format (SYS-CON Media)
Cyberonics, Inc. today announced that it received FDA approval for a harmonized/modularized VNS Therapy(TM) System labeling format and FDA approval to market the VNS Therapy Model 250 Version 7.1.4 Programming Software in the United States.